Genetically Determined Adverse Drug Reactions Involving Metabolism
- 1 July 1993
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 9 (1) , 60-77
- https://doi.org/10.2165/00002018-199309010-00006
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Published by Elsevier ,2005
- Dextromethorphan An Overview of Safety IssuesDrug Safety, 1992
- Fluoxetine‐Induced Tricyclic Toxicity: Extent and DurationThe Journal of Clinical Pharmacology, 1991
- ParoxetineDrugs, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by PropafenoneNew England Journal of Medicine, 1990
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Effects of Coadministration of Propafenone on the Pharmacokinetics of Digoxin in Healthy Volunteer SubjectsThe Journal of Clinical Pharmacology, 1989
- Genetically Determined Variability in Acetylation and Oxidation Therapeutic ImplicationsDrugs, 1985
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978